In Search of the Second Hit in Pulmonary Arterial Hypertension
2019; Lippincott Williams & Wilkins; Volume: 124; Issue: 1 Linguagem: Inglês
10.1161/circresaha.118.314270
ISSN1524-4571
Autores Tópico(s)Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
ResumoHomeCirculation ResearchVol. 124, No. 1In Search of the Second Hit in Pulmonary Arterial Hypertension Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBIn Search of the Second Hit in Pulmonary Arterial Hypertension Peiran Yang and Paul B. Yu Peiran YangPeiran Yang From the Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. and Paul B. YuPaul B. Yu Correspondence to Paul B. Yu, MD, PhD, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Thorn Biosciences 1219, 20 Shattuck St, Boston, MA 02115. Email E-mail Address: [email protected] From the Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Originally published3 Jan 2019https://doi.org/10.1161/CIRCRESAHA.118.314270Circulation Research. 2019;124:6–8This article is a commentary on the followingCLIC4/Arf6 PathwaySince the discovery of mutations in BMPR2 (bone morphogenetic protein receptor type II) gene in patients with pulmonary arterial hypertension (PAH), growing evidence from human genetics has supported a critical role for imbalanced signaling of the TGF-β (transforming growth factor-β) family, such that deficient BMP and maladaptive TGF-β signaling appear to contribute.1,2 BMPRII expression is not only reduced in PAH patients harboring mutations in BMPR2 but also in mutation-negative idiopathic PAH,3 suggesting additional environmental or epigenetic factors may downregulate this receptor. Several possible mechanisms have been proposed, including estrogen signaling,4 interleukin-6–mediated inflammation,5 TNFα (tumor necrosis factor-α)-induced cleavage,6 and other factors driving the ubiquitination and degradation of BMPRII.7 The reduced penetrance of PAH-associated BMPR2 mutations is consistent with the need for additional factors, such as vascular injury or inflammation for triggering disease.8 In search of this missing link, Abdul-Salam et al9 describe in the current issue a novel pathway that may integrate hypoxia and inflammation to regulate endothelial BMPRII expression and the balance between BMP and TGF-β signaling.Article, see p 52This team had previously described a proteomic analysis of lungs from PAH patients and control subjects for differentially expressed proteins.10 A key finding was increased expression of CLIC4 (chloride intracellular channel 4) in PAH tissues, localized predominantly to endothelial cells (ECs) in vascular lesions, with corresponding increases in CLIC4 observed in plasma and blood-derived ECs from idiopathic PAH patients and in rat models of pulmonary hypertension (PH).10 Increased levels of CLIC4 altered barrier function, survival, and angiogenic activity of ECs. CLIC4 modulated p65-mediated activation of NFκB (nuclear factor kappa-light-chain-enhancer of activated B cells), which in turn regulated HIF-1α (hypoxia-inducible factor-1α), vascular endothelial growth factor, and endothelin-1. Consistent with a pathogenetic role, CLIC4 knockout mice developed less-severe PH under hypoxia.11 Spiekerkoetter et al12 showed previously that CLIC4 is regulated by BMPRII in pulmonary arterial smooth muscle cells and modulates cell motility by altering alignment of myosin and actin filaments and the distribution and activation of small GTPases, suggesting CLIC4 exerts cell type–dependent effects in the pulmonary vasculature (Figure). Importantly, despite its name CLIC4, can only form poorly selective ion channels in artificial bilayers; instead, it may function as a scaffolding protein coupling the membrane to the cytoskeleton via protein interactions.13 Taken together, these studies demonstrated potentially important cell-specific roles of CLIC4 in regulating inflammation and aberrant vascular function in PAH.Download figureDownload PowerPointFigure. Effects of CLIC4 in pulmonary arterial endothelial cell (PAEC) and pulmonary arterial smooth muscle cell (PASMC). CLIC4 (chloride intracellular channel 4) expression and Arf6 (ADP ribosylation factor 6) activity are both increased in pulmonary hypertension. In PAEC, CLIC4 acts via Arf6 to reduce BMPRII (bone morphogenetic protein receptor type II) expression and signaling by promoting lysosomal degradation and reducing recycling of the receptor protein. CLIC4 also increases TGF-β (transforming growth factor-β) and NFκB (nuclear factor kappa-light-chain-enhancer of activated B cells) signaling, resulting in increased proliferation, inflammation, and permeability, reduced apoptosis, dysregulated angiogenesis, and vascular remodeling.9 In PASMC, BMPRII signaling maintains expression of CLIC4, responsible for activation of Rac1 and RhoA and cytoskeletal rearrangements required for human PASMC migration.12 Solid arrows denote regulatory effects; dotted arrows denote translocation. Blue text describes the effect of CLIC4 signaling on cell homeostasis. BMP2, BMP9 indicate bone morphogenetic proteins 2 and 9; ET-1, endothelin 1; GIT1/2, ADP ribosylating factor GTPase-activating proteins 1 and 2; HIF-1α, hypoxia-inducible factor-1α; MHCIIA, myosin heavy chain IIA; MMP2, matrix metalloproteinase-2; Rac-1, Ras-related C3 botulinum toxin substrate 1; RAGE, receptor for advanced glycation endproducts; RhoA, Ras homolog gene family member A; ROS, reactive oxygen species; S100A4/Mts1, S100 calcium-binding protein A4; TNFα, tumor necrosis factor-α; and VEGF, vascular endothelial growth factor.In the current study, a proteomic analysis of human pulmonary arterial ECs revealed interactions of CLIC4 with proteins involved in endosomal trafficking, lysosomal function, and inflammation, including GTPase-activating proteins GIT1 and GIT2 (ADP ribosylating factor GTPase-activating proteins 1 and 2), and clathrin. CLIC4 enhanced activity of Arf6 (ADP ribosylation factor 6) by interacting with GIT1/GIT2 to maintain Arf6 in the active form. Using Arf6 siRNA and pharmacological inhibition with secinH3, Arf6 was shown to mediate known functions of CLIC4, including activation of NFκB, HIF-1α, and tube formation (Figure). Importantly, CLIC4 negatively regulated BMPRII expression and BMP9-SMAD1/5 signaling, while enhancing TGF-β–SMAD3 signaling in human pulmonary arterial ECs.9 CLIC4, acting via Arf6, was found to increase clathrin-mediated internalization and lysosomal degradation, while reducing gyrating clathrin responsible for recycling endosomal cargo to cell surface, thereby reducing BMPRII expression in human pulmonary arterial ECs9 and perturbing the balance between BMP and TGF-β signaling. Interestingly, Arf6 activity was increased in blood-derived EC from idiopathic PAH patients,9 suggesting the relevance of this mechanism in human disease. The mechanistic contribution of these findings was tested in animal models of PH, in which elevated CLIC4 was observed in conjunction with activation of Arf6 and NFκB and reduced BMPRII in the lung. Inhibiting CLIC4 and Arf6 using CLIC4 siRNA and secinH3 attenuated experimental PH, reduced CLIC4/Arf activation, and restored pulmonary BMPRII expression.9 Thus, in pursuing downstream effectors and pathways modulated by CLIC4, Arf6 was uncovered as an important mediator at the interface between CLIC4, BMP/TGF-β signaling, and inflammatory signaling. These findings provide a potential explanation for the reduction of BMPRII expression in the pulmonary vasculature of idiopathic PAH patients, addressing an incomplete understanding of how BMP signaling deficiency may arise in acquired forms of PAH, while defining Arf6 and modification of endosomal trafficking as potentially druggable targets in PAH.These important findings raise several questions for subsequent investigation. For example, what are the drivers of increased CLIC4 expression in PAH? The authors found increased pulmonary expression of CLIC4 and Arf6 activity 3 days after monocrotaline injection, at which point BMPRII expression was reduced but PH and right ventricular hypertrophy were not yet established.9 Early upregulation of CLIC4 in this model could represent a secondary response to changes related to the disease state because CLIC4 expression is regulated by hypoxia, reactive oxygen species, DNA damage, and inflammation.11 On the contrary, the authors suggest that BMPRII deficiency may induce a state of heighted inflammatory and oxidative stress that could induce CLIC4 in vivo9; however, in their own previous work, silencing BMPRII expression in ECs did not alter CLIC4 protein levels.11 A prior study demonstrated that TGF-β promotes the expression of CLIC4 and Schnurri-2 and their translocation to the nucleus of keratinocytes, whereby nuclear CLIC4 associates with phosphorylated SMAD2 and SMAD3 to prevent their dephosphorylation and inactivation.14 It is possible that this positive feedback loop could propagate TGF-β signaling in PAH, worsening the imbalance between BMP and TGF-β while BMPRII expression is suppressed by CLIC4. Understanding the specific drivers of CLIC4 expression in the pulmonary vasculature could reveal early events in the development of PAH or factors driving its progression.The identification of CLIC4-interacting proteins provides new mechanistic insights into the impact of CLIC4, now confirmed via CLIC4 siRNA in SUGEN/hypoxia-exposed mice, consistent with the attenuated hypoxia-induced PH in CLIC4 knockout mice.11 Intriguingly, the chloride channel function of CLIC4 may not be required for regulation of NFκB and BMPRII, demonstrated by lack of impact of chloride channel blocker IAA-94. Changes in plasma membrane anion permeability caused by CLIC4 overexpression and potential electrophysiological effects of this protein deserve further investigation. In support of its specificity for Arf6, CLIC4 did not affect the closely related Arf1—a Golgi-associated Arf protein. The roles of Golgi-associated Arf proteins could be further investigated in the context of dysfunctional protein trafficking in PAH. Although the authors demonstrated a direct interaction between CLIC4 and GIT1, the precise mechanisms by which this complex modulates Arf6 activity are a subject for further study. It was emphasized that CLIC4 regulates the activity, not the expression levels of Arf6, paralleling observations that Arf6 activity and not expression are increased in PAH blood-derived ECs. The current in vivo studies used secinH3—a small molecule inhibitor that blocks Arf6 activation by inhibiting the GDP for GTP exchange mediated by Arf guanine nucleotide exchange factors.15 Although the impact of secinH3 supports the role of Arf6, future studies could test the contribution of Arf6 in vivo by gene targeting or ablation. Although there are safety concerns associated with secinH3, which caused hepatic insulin resistance in mice,15 the current study found no gross abnormalities in the liver and other organs with secinH3 treatment. An upcoming clinical trial of the Arf6 inhibitor NAV-5093 (Navigen Pharmaceuticals) in acute respiratory distress syndrome may provide further insight on the safety of inhibiting Arf6 (http://www.a6pharmaceuticals.com/technology) while providing a route for translation.The authors suggest that CLIC4/Arf6-induced clathrin-mediated endocytosis, lysosomal trafficking, and acidification are the principal drivers of reduced BMPRII expression in PAH.9 Previous studies demonstrated that BMPRII expression in vascular cells is constitutively regulated via a lysosomal degradative pathway7 that can be blocked using lysosomal inhibitor chloroquine, and in this context, the influence of CLIC4-regulated gyrating clathrin and ubiquitination on lysosomal trafficking could be clarified. Subsequent investigations could explore how CLIC4 enhances TGFβ-SMAD3 signaling and why BMPRII appears to be preferentially targeted by CLIC4 signaling. Finally, the differential impact of CLIC4 on the endothelium versus pulmonary arterial smooth muscle12 could be revisited in light of the current proposal to inhibit CLIC4/Arf6 systemically.In summary, Abdul-Salam et al have reported a novel mechanism by which CLIC4 regulates Arf6 in the endothelium to attenuate BMPRII-mediated BMP9 signaling and potentiate TGF-β, linking CLIC4 to the critical BMP/TGFβ-signaling pathway. Activation of CLIC4 signaling by environmental stressors, such as hypoxia and inflammation, represents a plausible second hit for promoting the imbalance of signaling in PAH and may provide a new therapeutic route for intervention.Sources of FundingThis work was supported by funding from the US National Institutes of Health (P.B. Yu: HL131910, HL132742, and AR057374).DisclosuresNone.FootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.Correspondence to Paul B. Yu, MD, PhD, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Thorn Biosciences 1219, 20 Shattuck St, Boston, MA 02115. Email [email protected]harvard.eduReferences1. Machado RD, Southgate L, Eichstaedt CA, et al. Pulmonary arterial hypertension: a current perspective on established and emerging molecular genetic defects.Human Mutation. 2015; 36:1113–1127.CrossrefMedlineGoogle Scholar2. Yung LM, Nikolic I, Paskin-Flerlage SD, Pearsall RS, Kumar R, Yu PB. A selective transforming growth factor-β ligand trap attenuates pulmonary hypertension.Am J Respir Crit Care Med. 2016; 194:1140–1151. doi: 10.1164/rccm.201510-1955OCCrossrefMedlineGoogle Scholar3. Atkinson C, Stewart S, Upton PD, Machado R, Thomson JR, Trembath RC, Morrell NW. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor.Circulation. 2002; 105:1672–1678.LinkGoogle Scholar4. Austin ED, Hamid R, Hemnes AR, Loyd JE, Blackwell T, Yu C, Phillips Iii JA, Gaddipati R, Gladson S, Gu E, West J, Lane KB. BMPR2 expression is suppressed by signaling through the estrogen receptor.Biol Sex Differ. 2012; 3:6.CrossrefMedlineGoogle Scholar5. Brock M, Trenkmann M, Gay RE, Michel BA, Gay S, Fischler M, Ulrich S, Speich R, Huber LC. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway.Circ Res. 2009; 104:1184–1191. doi: 10.1161/CIRCRESAHA.109.197491LinkGoogle Scholar6. Hurst LA, Dunmore BJ, Long L, Crosby A, Al-Lamki R, Deighton J, Southwood M, Yang X, Nikolic MZ, Herrera B, Inman GJ, Bradley JR, Rana AA, Upton PD, Morrell NW. TNFα drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and altering NOTCH signalling.Nat Commun. 2017; 8:14079. doi: 10.1038/ncomms14079CrossrefMedlineGoogle Scholar7. Durrington HJ, Upton PD, Hoer S, Boname J, Dunmore BJ, Yang J, Crilley TK, Butler LM, Blackbourn DJ, Nash GB, Lehner PJ, Morrell NW. Identification of a lysosomal pathway regulating degradation of the bone morphogenetic protein receptor type II.J Biol Chem. 2010; 285:37641–37649. doi: 10.1074/jbc.M110.132415CrossrefMedlineGoogle Scholar8. Morrell NW, Bloch DB, ten Dijke P, Goumans MJ, Hata A, Smith J, Yu PB, Bloch KD. Targeting BMP signalling in cardiovascular disease and anaemia.Nat Rev Cardiol. 2016; 13:106–120. doi: 10.1038/nrcardio.2015.156CrossrefMedlineGoogle Scholar9. Abdul-Salam VB, Russomanno G, Chien-Nien C, Mahomed AS, Yates LA, Wilkins MR, Zhao L, Gierula M, Dubois O, Schaeper U, Endruschat J, Wojciak-Stothard B. CLIC4/Arf6 pathway: a new lead in BMPRII inhibition in pulmonary hypertension.Circ Res. 2019; 124:52–65. doi: 10.1161/CIRCRESAHA.118.313705LinkGoogle Scholar10. Abdul-Salam VB, Wharton J, Cupitt J, Berryman M, Edwards RJ, Wilkins MR. Proteomic analysis of lung tissues from patients with pulmonary arterial hypertension.Circulation. 2010; 122:2058–2067. doi: 10.1161/CIRCULATIONAHA.110.972745LinkGoogle Scholar11. Wojciak-Stothard B, Abdul-Salam VB, Lao KH, et al. Aberrant chloride intracellular channel 4 expression contributes to endothelial dysfunction in pulmonary arterial hypertension.Circulation. 2014; 129:1770–1780. doi: 10.1161/CIRCULATIONAHA.113.006797LinkGoogle Scholar12. Spiekerkoetter E, Guignabert C, de Jesus Perez V, Alastalo TP, Powers JM, Wang L, Lawrie A, Ambartsumian N, Schmidt AM, Berryman M, Ashley RH, Rabinovitch M. S100A4 and bone morphogenetic protein-2 codependently induce vascular smooth muscle cell migration via phospho-extracellular signal-regulated kinase and chloride intracellular channel 4.Circ Res. 2009; 105:639–647, 13 p following 647. doi: 10.1161/CIRCRESAHA.109.205120LinkGoogle Scholar13. Littler DR, Harrop SJ, Goodchild SC, Phang JM, Mynott AV, Jiang L, Valenzuela SM, Mazzanti M, Brown LJ, Breit SN, Curmi PM. The enigma of the CLIC proteins: ion channels, redox proteins, enzymes, scaffolding proteins?FEBS Lett. 2010; 584:2093–2101. doi: 10.1016/j.febslet.2010.01.027CrossrefMedlineGoogle Scholar14. Shukla A, Malik M, Cataisson C, Ho Y, Friesen T, Suh KS, Yuspa SH. TGF-beta signalling is regulated by Schnurri-2-dependent nuclear translocation of CLIC4 and consequent stabilization of phospho-Smad2 and 3.Nat Cell Biol. 2009; 11:777–784. doi: 10.1038/ncb1885CrossrefMedlineGoogle Scholar15. Hafner M, Schmitz A, Grüne I, Srivatsan SG, Paul B, Kolanus W, Quast T, Kremmer E, Bauer I, Famulok M. Inhibition of cytohesins by SecinH3 leads to hepatic insulin resistance.Nature. 2006; 444:941–944. doi: 10.1038/nature05415CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited ByLiu B, Wei Y, Fan X, Hu X, Chen Z, Liu X, Xu Y, Wang L, Wang T, Ruiz M, Dupuis J, Yuan P, Liu J, Huang S, Zhu L, Jing Z and Hu Q (2022) Calcium Sensing Receptor Variants Increase Pulmonary Hypertension Susceptibility, Hypertension, 79:7, (1348-1360), Online publication date: 1-Jul-2022. Amin E, Austin E, Parker C, Colglazier E, Nawaytou H, Leary P, Hemnes A, Teitel D and Fineman J (2020) Novel Documentation of Onset and Rapid Advancement of Pulmonary Arterial Hypertension without Symptoms in BMPR2 Mutation Carriers: Cautionary Tales?, American Journal of Respiratory and Critical Care Medicine, 10.1164/rccm.202005-1611LE, 202:11, (1587-1589), Online publication date: 1-Dec-2020. Hiepen C, Jatzlau J, Hildebrandt S, Kampfrath B, Goktas M, Murgai A, Cuellar Camacho J, Haag R, Ruppert C, Sengle G, Cavalcanti-Adam E, Blank K, Knaus P and Mullins M (2019) BMPR2 acts as a gatekeeper to protect endothelial cells from increased TGFβ responses and altered cell mechanics, PLOS Biology, 10.1371/journal.pbio.3000557, 17:12, (e3000557) van Uden D, Koudstaal T, van Hulst J, Vink M, van Nimwegen M, van den Toorn L, Chandoesing P, van den Bosch A, Kool M, Hendriks R and Boomars K (2022) Peripheral Blood T Cells of Patients with IPAH Have a Reduced Cytokine-Producing Capacity, International Journal of Molecular Sciences, 10.3390/ijms23126508, 23:12, (6508) Related articlesCLIC4/Arf6 PathwayVahitha B. Abdul-Salam, et al. Circulation Research. 2019;124:52-65 January 4, 2019Vol 124, Issue 1 Advertisement Article InformationMetrics © 2018 American Heart Association, Inc.https://doi.org/10.1161/CIRCRESAHA.118.314270PMID: 30605416 Originally publishedJanuary 3, 2019 KeywordsEditorialsguanine nucleotide exchange factorshypertension, pulmonarychloride channelshumansPDF download Advertisement SubjectsCell Signaling/Signal TransductionPulmonary HypertensionSmooth Muscle Proliferation and DifferentiationTranslational StudiesVascular Biology
Referência(s)